Search the Newsreel

Pyxis Oncology (PYXS) Projected to Release Quarterly Earnings on Thursday

Pyxis Oncology (NASDAQ:PYXS) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 13th. Analysts anticipate a loss of $0.34 per share and revenue of $33,000, continuing a trend of projected annual losses of around $1 per share. Despite mixed …

CG Oncology (NASDAQ: CGON) posts $139.3M half-year loss with $1,028.3M cash

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology (Nasdaq: ALXO) announced its financial results for the second quarter ended June 30, 2026, highlighting progress in its clinical programs, including the ASPEN-09-Breast trial for evorpacept and the Phase 1 trial for ALX2004. The company reported a strengthened balance sheet, with cash …

CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

CG Oncology Inc. reported its second-quarter 2026 financial results, highlighting significant progress in clinical, regulatory, manufacturing, and commercial-readiness initiatives. Key milestones include anticipated Phase 3 topline data for PIVOT-006, expected BLA completion for HR BCG-unresponsive NMIBC in Q4 2026, and the publication of BOND-003 …

CG Oncology expects bladder cancer trial data soon; cash through 2029

CG Oncology reported a Q2 2026 net loss of $79.1 million on $1.2 million in revenue, primarily due to increased R&D and G&A expenses. The company maintains a strong cash position of approximately $1.0 billion, which is projected to fund operations through 2029, supporting …

Cullinan to begin potentially registrational acute myeloid leukemia study in Q3

Cullinan Therapeutics reported a Q2 2026 net loss of $53.7 million but maintained a strong cash position of $356 million, providing a runway into 2029. The company announced several upcoming clinical milestones for its immunology and oncology pipeline, including the initiation of a potentially …

Pyxis Oncology Inc (PYXS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Pyxis Oncology Inc (PYXS), highlighting its current earnings forecast score, average price target, and analyst ratings. It indicates that 10 analysts have given the stock a "Buy" trend, with an average price target of $7.70. The article …

ALX Oncology (NASDAQ:ALXO) Issues Earnings Results

CG Oncology (CGON) Earnings Date and Reports 2026

Oncology Institute (NASDAQ:TOI) Issues Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Cullinan Oncology earnings up next: Can pipeline justify cash burn?

Cullinan Therapeutics Inc. is set to report second-quarter earnings, with analysts expecting a wider loss per share. The pre-revenue biotech, with a $1.08 billion market cap, is advancing two late-stage oncology programs, CLN-049 and zipalertinib, which have garnered bullish Wall Street sentiment and significant …

Dimensional Fund Advisors LP Sells 22,459 Shares of CG Oncology, Inc. $CGON

Dimensional Fund Advisors LP has reduced its stake in CG Oncology (NASDAQ:CGON) by selling 22,459 shares, though it still holds 438,673 shares valued at approximately $29.7 million. Despite this sale, institutional investors collectively own 26.56% of the company, and analysts maintain a "Moderate Buy" …

CGON (CGON) insider Ambaw Bellete plans 25,000-share stock sale via broker

CG Oncology, Inc. (CGON) insider Ambaw Bellete has filed a Form 144 notice to sell up to 25,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,837,500.00. The shares, acquired via a stock option exercise, are …

Enterprise value to EBIT forward of Pyxis Oncology, Inc. – NASDAQ:PYXS

This article provides financial information for Pyxis Oncology, Inc. (NASDAQ: PYXS), specifically focusing on its enterprise value to EBIT forward ratio. It highlights that the data is presented by TradingView, a platform offering various market tools and financial insights. The content is primarily a …

Citius Oncology's LYMPHIR is in 42 institutions with near-universal coverage

Kura Oncology to Report Second Quarter Financial Results

Kura Oncology, Inc. announced it will report its second quarter 2026 financial results after market close on Wednesday, August 12, 2026. Management will host a webcast and conference call at 4:30 p.m. ET to discuss the results and provide a corporate update. The company …

Cancer drugmaker Kura Oncology schedules Aug. 12 webcast

Kura Oncology (Nasdaq: KURA) will report its second quarter 2026 financial results after the close of U.S. financial markets on Wednesday, August 12, 2026. The company will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the …

The Oncology Institute, Inc. Revenue Breakdown – NASDAQ:STLN

The Oncology Institute, Inc. (NASDAQ: STLN) generated $502.73 million in revenue last year, with its Dispensary segment being the top performer, contributing $269.18 million. The majority of its revenue, $502.73 million, originated from the United States. This indicates a strong domestic market for the …

Top Healthcare Stocks to Watch: Why Is OncoSil Medical (ASX:OSL) in Focus?

Behind Concord Healthcare (2453.HK)'s Positive Profit Alert: Gross Profit Surges More Than 160-Fold as Proton Therapy Enters a New Phase of Scalable Growth

Concord Healthcare (2453.HK) has issued a positive profit alert, projecting a significant increase in gross profit for the first half of 2026, surging over 160-fold year-on-year. This remarkable growth is attributed to its proton therapy infrastructure entering a commercialization stage, with the Guangzhou Concord …

ETFs Investing in BridgeBio Oncology Therapeutics, Inc. Stocks

This article lists several ETFs that hold BridgeBio Oncology Therapeutics, Inc. (BBOT) stocks, providing details such as market value, weight, issuer, management style, expense ratio, AUM, price change, and NAV total return. The ETFs highlighted primarily focus on the healthcare and biotechnology sectors, offering …

ALX Oncology (ALXO) Projected to Post Earnings on Tuesday

ALX Oncology (NASDAQ:ALXO) is expected to report its Q2 2026 earnings before market open on Tuesday, August 11th, with analysts projecting a loss of $0.15 per share. The company previously missed Q1 estimates, reporting a $0.17 per share loss. ALXO shares recently saw a …

Price to earnings forward of CG Oncology, Inc. – NASDAQ:CGON

This article provides the "Price to earnings forward" metric for CG Oncology, Inc. (NASDAQ: CGON) on TradingView. It appears to be a financial data point displayed within a larger financial analysis platform. The specific value and change percentage are indicated as data fields.

Pyxis Oncology (NASDAQ:PYXS) Raised to Strong-Buy at Wells Fargo & Company

Wells Fargo & Company has upgraded Pyxis Oncology (NASDAQ:PYXS) to a "strong-buy" rating. Despite the upgrade, the company reported a quarterly EPS of -$0.37, missing analyst estimates. Institutional investors and hedge funds currently hold 39.07% of the company's stock, which has an average analyst …

Cash per share of The Oncology Institute, Inc. – NASDAQ:STLN

This article focuses solely on "Cash per share of The Oncology Institute, Inc. – NASDAQ:STLN". It provides the stock symbol STLN, identifies it as being listed on the Nasdaq Stock Market, and categorizes the company under Health Services / Medical/Nursing Services. The content is …

Champions Oncology (NASDAQ:CSBR) Stock Price Crosses Below 200 Day Moving Average - Here's Why

Champions Oncology (NASDAQ:CSBR) saw its stock price fall below its 200-day moving average to $5.76, amidst a downgrade from Weiss Ratings to "sell (E+)." Despite beating quarterly earnings expectations with $0.01 EPS against an anticipated $0.05 loss and revenues of $13.84 million, the company …

Alphamab Oncology Announces Acceptance of NDA for Anbenitamab as Neoadjuvant Treatment for Her2+ Breast Cancer by the NMPA

Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Recommendation of "Hold" by Analysts

Cardiff Oncology, Inc. (NASDAQ:CRDF) has received an average "Hold" recommendation from analysts, with a 12-month average price target of $7.50. The stock is currently trading near its 12-month low, and several firms have recently downgraded it. Despite the negative analyst sentiment and a missed …

The Oncology Institute, Inc. will Change its Ticker to STLN from TOI

The Oncology Institute, Inc. announced that its stock ticker symbol on the Nasdaq Capital Market will change from TOI to STLN, effective August 4, 2026. This change follows the company's recent name change to Starling Oncology, Inc.

Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC

How Kura Oncology Inc. (KURA) Affects Rotational Strategy Timing

This article analyzes Kura Oncology Inc. (KURA) for rotational strategy timing, highlighting weak near- and mid-term sentiment but a strong long-term outlook. It details specific trading strategies, including long, breakout, and short positions, with entry points, targets, and stop losses derived from AI models. …

The Oncology Institute Changes Name to Starling Oncology

The Oncology Institute, Inc. has officially changed its name to Starling Oncology, Inc. The company, which manages community-based oncology practices across 86 clinic locations in five states, continues to provide medical oncology services, including physician services, infusion, radiation, and clinical trials. This name change …

Wells Fargo initiates Pyxis Oncology stock with overweight rating By Investing.com

Wells Fargo has initiated coverage on Pyxis Oncology Inc. (NASDAQ:PYXS) with an overweight rating and a price target of $12.00, citing the potential of its MICVO treatment for head and neck squamous cell carcinoma. Despite a recent nine percent decline, the stock has seen …

Concorde International Group Ltd Revenue Breakdown – NASDAQ:CIGL

Concorde International Group Ltd (NASDAQ:CIGL) reported its revenue breakdown, highlighting Singapore as its largest contributor. The company generated $12.48 million USD from Singapore last year, an increase from $10.49 million USD the prior year. The breakdown shows revenue by source and by country.

Wells Fargo Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $12

Wells Fargo has initiated coverage on Pyxis Oncology (PYXS.US) with a Buy rating. The firm has set a target price of $12 for the company's stock. This initiation suggests a positive outlook from Wells Fargo regarding Pyxis Oncology's future performance.

The Oncology Institute Rebrands as Starling Oncology

The Oncology Institute (TOI), a major value-based oncology group in the U.S., has officially rebranded as Starling Oncology, Inc. The company's stock will now trade on Nasdaq under the new ticker symbol "STLN" starting August 4, 2026. This rebrand signifies the company's growth and …